Product News and Recalls

FDA to Consider new Yaz/Yasmin Warnings Next Month

December 8 Meeting Scheduled to Discuss 6 Studies Showing Increased Risk of Blood Clots

The FDA will hold hearings next month to consider the risks of blood clots associated with Yaz, Yasmin, Ocella, and Beyaz. Although approximately six studies now show an increased risk, the FDA has not yet determined whether to officially update the warnings on these pills. The agency is widely expected to make a decision at or shortly after the hearings to be held on December 8, 2011.

If you suffered a blood clot, pulmonary embolism, or stroke, while on Yaz, contact us to discuss your options for pursuing compensation, or have your questions answered by a qualified attorney, with no obligation. Lopez McHugh currently has a bellwether case being prepared for trial–it may be one of the first in the nation to be tried in the Yaz litigation.

Yaz contains a compound created by Bayer called drospirenone, a synthetic progestogen that may elevate the levels of potassium in the body. Side effects include heart attack, stroke, pulmonary embolism, blood clots, and even death.